Using 2-HOBA to treat pulmonary hypertension
2-HOBA for Treatment of Pulmonary Hypertension
['FUNDING_OTHER'] · MTI BIOTECH, INC. · NIH-10916207
This study is looking at a new treatment called 2-HOBA to help people with pulmonary hypertension by improving heart function and reducing pressure in the lungs, and it includes both lab tests and early trials with patients to see how well it works and if it's safe.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MTI BIOTECH, INC. (nih funded) |
| Locations | 1 site (AMES, UNITED STATES) |
| Trial ID | NIH-10916207 on ClinicalTrials.gov |
What this research studies
This research investigates the use of a small molecule called 2-HOBA to address metabolic problems associated with pulmonary hypertension (PH). By targeting the mitochondrial lysine deacetylase SIRT3, the study aims to break a harmful cycle that exacerbates the condition. The approach involves both laboratory experiments and early human trials to assess the safety and effectiveness of 2-HOBA in reducing pulmonary vascular resistance and improving heart function. Patients may be involved in trials to evaluate the impact of this treatment on their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary hypertension, particularly those experiencing metabolic complications related to the condition.
Not a fit: Patients with pulmonary hypertension who do not have metabolic issues or those with advanced heart failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly improves heart function and reduces symptoms for patients with pulmonary hypertension.
How similar studies have performed: Preliminary studies and Phase I trials have shown promising results with similar approaches, indicating potential for success in this Phase II project.
Where this research is happening
AMES, UNITED STATES
- MTI BIOTECH, INC. — AMES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RATHMACHER, JOHN A — MTI BIOTECH, INC.
- Study coordinator: RATHMACHER, JOHN A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.